Beigene Ltd ADR (NQ: BGNE )
192.50
-2.15
(-1.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 19, 2024
Add to My Watchlist
Headline News about Beigene Ltd ADR
![](https://g.foolcdn.com/editorial/images/784080/investing-screen-analysis-investor-growth-stocks-getty.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/06/30/Moderna.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2024/06/17/cancer.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.png?width=1200&height=800&fit=crop)
Evaluating BeiGene: Insights From 6 Financial Analysts
April 24, 2024
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_2.jpeg?width=1200&height=800&fit=crop)
4 Analysts Assess BeiGene: What You Need To Know
March 27, 2024
Via Benzinga
![](https://cdn.pixabay.com/photo/2018/04/18/18/52/hands-3331229_960_720.jpg)
![](https://investorplace.com/wp-content/uploads/2022/05/large-cap-1600-1-1024x576.png)
![](https://cdn.benzinga.com/files/images/story/2024/05/26/yoga-LULU-Lululemon.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://talkmarkets.com/images/logos/talkmarkets.png)
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
![](https://cdn.benzinga.com/files/images/story/2024/04/28/Growth-Chart--Glowing-Rise-Up-Arrow-On-T_0.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2024/04/23/Movers.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.pixabay.com/photo/2018/04/18/18/52/hands-3331229_960_720.jpg)
Via Talk Markets
![](https://cdn.benzinga.com/files/images/story/2024/03/22/lululemon_athletica_-_logo.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2024/BGNE_0.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2024/03/13/image17.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2024/03/13/image33.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2024/BGNE.png?width=1200&height=800&fit=crop)
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
March 08, 2024
Via Benzinga
Exposures
Product Safety
![](https://cdn.benzinga.com/files/images/story/2024/Xpeng.jpeg?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600.png)
![](https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600.png)
![](https://cdn.benzinga.com/files/images/story/2024/cancer_7.jpeg?width=1200&height=800&fit=crop)
![](https://g.foolcdn.com/editorial/images/761232/biotech-researcher.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/china-covid-shutter3.jpeg?width=1200&height=800&fit=crop)
![](https://staticx-tuner.zacks.com/images/default_article_images/default35.jpg)
![](https://cdn.benzinga.com/files/hbm-holdings.jpg?width=1200&height=800&fit=crop)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.